The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Assessment of a novel immunological biomarker SNP panel from a phase III trial of Bacillus Calmette-Guérin (BCG) adjuvant treatment in stage III melanoma patients.
Connie Ging Ting Chiu
No relevant relationships to disclose
Donald L. Morton
No relevant relationships to disclose
Kelly Chong
No relevant relationships to disclose
Mirei Hoshino
No relevant relationships to disclose
Sharon Huang
No relevant relationships to disclose
Michael Bruce Nicholl
No relevant relationships to disclose
David Elashoff
No relevant relationships to disclose
Dave S. B. Hoon
No relevant relationships to disclose